|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12...1213141516171819202122...3940» |
- iloperidone / Generic mfg.
Enrollment change, Trial termination: Assessing the Effects of Fanapt (clinicaltrials.gov) - Sep 28, 2014
P4, N=19, Terminated, Sponsor: Northwestern University
N=50 --> 19 | Recruiting --> Terminated; Low recruitment
- Enrollment open: ACT-IP: Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis (clinicaltrials.gov) - Sep 28, 2014
P0, N=92, Recruiting, Sponsor: Department of Veterans Affairs
N=50 --> 19 | Recruiting --> Terminated; Low recruitment Not yet recruiting --> Recruiting
- Trial completion, Trial primary completion date: Theta Burst Transcranial Magnetic Stimulation as Treatment for Auditory Verbal Hallucinations (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=71, Completed, Sponsor: UMC Utrecht
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Jan 2014 --> May 2014
- ||| Clinical: Schizophrenia for "Life" - a Registry and Interview Study Among Elderly With Lifelong Schizophrenia (clinicaltrials.gov) - Sep 22, 2014
P=N/A, N=10404, Recruiting, Sponsor: Kjeld Andersen
- ulotaront (SEP-363856) / Otsuka, PsychoGenics
Enrollment closed, Trial primary completion date: Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia (clinicaltrials.gov) - Sep 22, 2014
P1, N=48, Active, not recruiting, Sponsor: Sunovion
Recruiting --> Completed | Trial primary completion date: Jan 2014 --> May 2014 Completed --> Active, not recruiting | Trial primary completion date: May 2014 --> Dec 2014
- Enrollment closed, Adverse events: Monitoring and Management for Metabolic Side Effects of Antipsychotics (clinicaltrials.gov) - Sep 22, 2014
P=N/A, N=120, Active, not recruiting, Sponsor: Department of Veterans Affairs
Completed --> Active, not recruiting | Trial primary completion date: May 2014 --> Dec 2014 Enrolling by invitation --> Active, not recruiting
- ||| nelonicline (ABT-126) / AbbVie
Enrollment closed, Trial primary completion date: Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680) (clinicaltrials.gov) - Sep 22, 2014
P2, N=271, Active, not recruiting, Sponsor: AbbVie
Enrolling by invitation --> Active, not recruiting Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Aug 2015
- BL-1020 / BioLineRx
Enrollment change: Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia (clinicaltrials.gov) - Sep 19, 2014
P2b, N=269, Terminated, Sponsor: BioLineRx, Ltd.
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Aug 2015 N=435 --> 269
- Rykindo (risperidone extended release microspheres) / Luye Group
Enrollment open, Trial primary completion date: An Randomized Open-Label PK Study of LY03004 Compared to Risperdal (clinicaltrials.gov) - Sep 19, 2014
P1, N=16, Enrolling by invitation, Sponsor: Luye Pharma Group Ltd.
N=435 --> 269 Not yet recruiting --> Enrolling by invitation | Trial primary completion date: Aug 2014 --> Nov 2014
- |||| Rykindo (risperidone extended release microspheres) / Luye Group
Enrollment open, Enrollment change, Trial initiation date: Bioavailability of LY03004 and Risperdal (clinicaltrials.gov) - Sep 19, 2014
P1/2, N=100, Recruiting, Sponsor: Luye Pharma Group Ltd.
Not yet recruiting --> Enrolling by invitation | Trial primary completion date: Aug 2014 --> Nov 2014 Not yet recruiting --> Recruiting | N=70 --> 100 | Initiation date: Jun 2014 --> Sep 2014
- Trial primary completion date: Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia (clinicaltrials.gov) - Sep 16, 2014
P=N/A, N=26, Recruiting, Sponsor: University of North Carolina, Chapel Hill
Not yet recruiting --> Recruiting | N=70 --> 100 | Initiation date: Jun 2014 --> Sep 2014 Trial primary completion date: Jun 2014 --> Oct 2014
- Clinical: Non-Invasive Brain Stimulation for Medication-Resistant Auditory Hallucinations in Schizophrenia Patients (clinicaltrials.gov) - Sep 15, 2014
P=N/A, N=50, Not yet recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
- ||||| Perseris (risperidone sustained-release 1-month depot) / Indivior, Reckitt Benckiser, HLS Therap
Clinical: Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia (clinicaltrials.gov) - Sep 15, 2014
P3, N=500, Active, not recruiting, Sponsor: Reckitt Benckiser Pharmaceuticals Inc.
Trial primary completion date: Jun 2014 --> Oct 2014 Recruiting --> Active, not recruiting
- | lorazepam / Generic mfg., haloperidol / Generic mfg.
Trial completion, Trial primary completion date: Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia (clinicaltrials.gov) - Sep 15, 2014
P3, N=67, Completed, Sponsor: National Taiwan University Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Feb 2009 --> Jun 2009
- aripiprazole / Generic mfg., haloperidol / Generic mfg.
Phase classification: Arip_200901: Effects of Aripiprazole and Haloperidol on Mesolimbic System Functioning (clinicaltrials.gov) - Sep 12, 2014
P4, N=54, Completed, Sponsor: Oslo University Hospital
Recruiting --> Completed | Trial primary completion date: Feb 2009 --> Jun 2009 Phase classification: P1 --> P4
- |||| F17464 / Pierre Fabre
Enrollment open: F17464 in Acute Schizophrenia Trial (clinicaltrials.gov) - Sep 12, 2014
P2, N=142, Recruiting, Sponsor: Pierre Fabre Medicament
Phase classification: P1 --> P4 Not yet recruiting --> Recruiting
- | Aristada once-monthly (aripiprazole lauroxil once-monthly formulation) / Alkermes
Enrollment closed, Trial primary completion date: OLE: A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) (clinicaltrials.gov) - Sep 12, 2014
P3, N=500, Active, not recruiting, Sponsor: Alkermes, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Apr 2015
- | L-threonic acid magnesium salt (NRCT-101) / Neurocentria
New P4 trial: Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia (clinicaltrials.gov) - Sep 11, 2014
P4, N=60, Recruiting, Sponsor: Northwestern University
- Trial primary completion date: Cognitive Remediation in 22q11DS (clinicaltrials.gov) - Sep 10, 2014
P=N/A, N=36, Active, not recruiting, Sponsor: Duke University
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Apr 2015 Trial primary completion date: Mar 2014 --> Dec 2014
- eszopiclone / Generic mfg.
Enrollment change: Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia (clinicaltrials.gov) - Sep 9, 2014
P=N/A, N=25, Completed, Sponsor: Massachusetts General Hospital
Trial primary completion date: Mar 2014 --> Dec 2014 N=45 --> 25
- ||||| Nuplazid (pimavanserin) / Acadia Pharma
Enrollment change: A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis (clinicaltrials.gov) - Sep 9, 2014
P3, N=123, Completed, Sponsor: ACADIA Pharmaceuticals Inc.
N=45 --> 25 N=240 --> 123
- memantine ER / Generic mfg., galantamine extended release / Generic mfg.
New P2 trial: Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia (clinicaltrials.gov) - Sep 9, 2014
P2, N=10, Not yet recruiting, Sponsor: Sheppard Pratt Health System
- carbidopa/levodopa / Generic mfg.
Trial primary completion date: Antipsychotic Augmentation With L-Dopa (clinicaltrials.gov) - Sep 8, 2014
P2, N=24, Recruiting, Sponsor: Centre for Addiction and Mental Health
N=240 --> 123 Trial primary completion date: Sep 2014 --> Sep 2015
- Phase classification: Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia (clinicaltrials.gov) - Sep 8, 2014
P4, N=66, Completed, Sponsor: Rutgers, The State University of New Jersey
Trial primary completion date: Sep 2014 --> Sep 2015 Phase classification: P=N/A --> P4
- | risperidone / Generic mfg., tropisetron / Generic mfg.
Trial completion, Trial primary completion date: Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia (clinicaltrials.gov) - Sep 8, 2014
P3, N=179, Completed, Sponsor: Baylor College of Medicine
Phase classification: P=N/A --> P4 Recruiting --> Completed | Trial primary completion date: Mar 2010 --> Feb 2011
- Trial primary completion date: Effect of Repetitive Transcranial Magnetic Stimulation on Resting State Brain Activity in Schizophrenia (clinicaltrials.gov) - Sep 5, 2014
P=N/A, N=30, Active, not recruiting, Sponsor: University of Arkansas
Recruiting --> Completed | Trial primary completion date: Mar 2010 --> Feb 2011 Trial primary completion date: Aug 2014 --> Jun 2015
- roluperidone (MIN-101) / Mitsubishi Tanabe, Minerva Neurosciences
New P1 trial: Pharmacokinetic Study of MIN-101 in Healthy Subjects (clinicaltrials.gov) - Sep 5, 2014
P1, N=36, Recruiting, Sponsor: Minerva Neurosciences
- | SKL-15508 / SK Bio
Enrollment open: A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia (clinicaltrials.gov) - Sep 5, 2014
P1/2, N=48, Recruiting, Sponsor: SK Life Science
Trial primary completion date: Aug 2014 --> Jun 2015 Not yet recruiting --> Recruiting
- Enrollment open: The Effect of Nitric Oxide on Spatial Working Memory in Patients With Schizophrenia - Pilot Study (clinicaltrials.gov) - Sep 5, 2014
P1, N=30, Recruiting, Sponsor: King's College London
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Doria (risperidone extended release) / ROVI Pharmaceuticals Laboratories
Enrollment closed, Enrollment change: PRISMA-2: Pharmacokinetics and Tolerability Study of Risperidone ISM (clinicaltrials.gov) - Sep 5, 2014
P2, N=70, Active, not recruiting, Sponsor: Rovi Pharmaceuticals Laboratories
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=48 --> 70
- ||||| asenapine / Generic mfg., olanzapine / Generic mfg.
Enrollment closed: Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689) (clinicaltrials.gov) - Sep 5, 2014
P3, N=170, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting | N=48 --> 70 Enrolling by invitation --> Active, not recruiting
- | balipodect (TAK-063) / Takeda
Trial completion: Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults (clinicaltrials.gov) - Sep 5, 2014
P1, N=27, Completed, Sponsor: Takeda
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis (clinicaltrials.gov) - Sep 5, 2014
P=N/A, N=32, Completed, Sponsor: University of Calgary
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Dec 2012 --> Aug 2014
- | Trial completion: Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia (clinicaltrials.gov) - Sep 5, 2014
P4, N=21, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Completed | Trial primary completion date: Dec 2012 --> Aug 2014 Recruiting --> Completed
- | JNJ-39393406 / J&J
New P2 trial: Novel Smoking Cessation Drug for Schizophrenia (clinicaltrials.gov) - Sep 4, 2014
P2, N=60, Not yet recruiting, Sponsor: K.N. Roy Chengappa
- Kuvan (sapropterin) / BioMarin, Daiichi Sankyo
Trial suspension: Kuvan in People With Schizophrenia and Schizoaffective Disorder (clinicaltrials.gov) - Aug 29, 2014
P1/2, N=60, Suspended, Sponsor: New York State Psychiatric Institute
Recruiting --> Completed Recruiting --> Suspended
- Trial completion, Compliance: How Can Rehospitalisations of Patients With Schizophrenia be Avoided? A Comparison Between Different Compliance Programs (clinicaltrials.gov) - Aug 29, 2014
P=N/A, N=896, Completed, Sponsor: Technische Universit
Recruiting --> Suspended Recruiting --> Completed
- lurasidone / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents (clinicaltrials.gov) - Aug 26, 2014
P2, N=10, Completed, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed Active, not recruiting --> Completed | N=30 --> 10 | Trial primary completion date: Dec 2014 --> Aug 2014
- Clinical data: ADARFEP: 3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=68, Completed, Sponsor: Fundación Marques de Valdecilla
- Trial completion, Enrollment change: D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=54, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed | N=30 --> 10 | Trial primary completion date: Dec 2014 --> Aug 2014 Recruiting --> Completed | N=120 --> 54
- ||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial initiation date: Brexpiprazole in Patients With Acute Schizophrenia (clinicaltrials.gov) - Aug 19, 2014
P3, N=465, Ongoing, Sponsor: H. Lundbeck A/S
Recruiting --> Completed | N=120 --> 54 Initiation date: Mar 2013 --> Sep 2013
- | Abilify MyCite (aripiprazole tablets embedded with sensor) / Otsuka
New P2 trial: Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole (clinicaltrials.gov) - Aug 19, 2014
P2, N=32, Not yet recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
- ||| olanzapine / Generic mfg.
Enrollment open: eVAluatIon of OLanzapine TreatmEnT (clinicaltrials.gov) - Aug 19, 2014
P=N/A, N=500, Recruiting, Sponsor: Elpen Pharmaceutical Co. Inc.
Initiation date: Mar 2013 --> Sep 2013 Not yet recruiting --> Recruiting
- Trial completion: Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia (clinicaltrials.gov) - Aug 19, 2014
P4, N=140, Completed, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Enrollment change, Trial termination, Trial primary completion date: Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia (clinicaltrials.gov) - Aug 15, 2014
P2, N=53, Terminated, Sponsor: Medicure
Recruiting --> Completed N=140 --> 53 | Recruiting --> Terminated | Trial primary completion date: Jun 2013 --> Aug 2012; modified formulation under investigation
- Enrollment change: TLC: A Brief Community Linkage Intervention for Dually Diagnosed Individuals (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=102, Completed, Sponsor: Department of Veterans Affairs
N=140 --> 53 | Recruiting --> Terminated | Trial primary completion date: Jun 2013 --> Aug 2012; modified formulation under investigation N=170 --> 102
- ||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Enrollment closed: Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia (clinicaltrials.gov) - Aug 15, 2014
P3, N=81, Active, not recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
N=170 --> 102 Not yet recruiting --> Active, not recruiting
- balipodect (TAK-063) / Takeda
Enrollment closed, Trial primary completion date: Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults (clinicaltrials.gov) - Aug 15, 2014
P1, N=27, Active, not recruiting, Sponsor: Takeda
Not yet recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2014 --> Aug 2014
- | OMS824 / Omeros
Trial completion, Enrollment change: Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects (clinicaltrials.gov) - Aug 15, 2014
P2, N=40, Completed, Sponsor: Omeros Corporation
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2014 --> Aug 2014 Recruiting --> Completed | N=32 --> 40
- Trial completion, Trial primary completion date: The Influence of Aerobic Exercise on Cognitive Functioning in Schizophrenia. (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=41, Completed, Sponsor: New York State Psychiatric Institute
Recruiting --> Completed | N=32 --> 40 Recruiting --> Completed | Trial primary completion date: Mar 2014 --> Jul 2014